News & Announcements
-
IB Opens Expanded Access Program
/**/ RNS Number : 7858T IQ-AI Limited 25 June 2024 June 25, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Opens Expanded Access Program New cancer treatment with the potential to slow brain tumor growth is now available to patients in the US with relapsed/refractory histologic or molecular glioblastoma Imaging Biometrics, LLC…
-
Clinical Trial Updates
/**/ RNS Number : 4807S IQ-AI Limited 14 June 2024 June 14, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI Reports Phase 1 Update and Shares Plans for Phase 2 Clinical Trial As the end of the Phase 1 clinical trial draws closer, IQ-AI Ltd (LSE: IQAI) shares the latest Phase 1 updates…
-
Result of AGM
/**/ RNS Number : 3271Q IQ-AI Limited 29 May 2024 IQ-AI Limited (“IQ-AI” or the “Company”) Result of AGM IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed. For information, the proxy votes received prior to the meeting were…
-
Major East Coast Health System Chooses IB Nimble
/**/ RNS Number : 5528P IQ-AI Limited 23 May 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Major East Coast Health System Chooses IB Nimble for Their Brain Metastases Program of Excellence Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), today announces that a leading cancer centre located…
-
Second FDA Rare Pediatric Disease Designation
/**/ RNS Number : 0655P IQ-AI Limited 20 May 2024 May 20, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Second U.S. FDA Rare Pediatric Disease Designation Granted to GaM For the Treatment of Pediatric-Type Diffuse High Grade Glioma (“HGG”) Further to the announcements made on 8 November 2023 and…